Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 196 of 196 entries
View as:

Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa

Phase: N/A Priority: Normal
NCT ID: NCT02626286 Org: User:
Start: 06/30/15 End: 01/05/21 Due: 01/05/22

HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study

Phase: N/A Priority: Normal
NCT ID: NCT04684758 Org: User:
Start: 04/14/21 End: 06/30/22 Due: 06/30/23

First-Line Treatment for HIV-2

Phase: N/A Priority: Normal
NCT ID: NCT02150993 Org: User:
Start: 01/26/16 End: 05/15/19 Due: 05/15/20

Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety

Phase: N/A Priority: Normal
NCT ID: NCT03519503 Org: User:
Start: 02/27/17 End: 02/15/18 Due: 02/15/19

Cohorte Nationale VIH-2

Phase: N/A Priority: Normal
NCT ID: NCT04658329 Org: User:
Start: 01/01/94 End: 09/30/22 Due: 09/30/23

Measure of Vaccine Effectiveness to Prevent Hospitalizations for Viral Respiratory Infections in Adults

Phase: N/A Priority: Normal
NCT ID: NCT05582239 Org: User:
Start: 01/20/23 End: 01/20/26 Due: 01/20/27

Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT02738502 Org: User:
Start: 07/06/16 End: 07/16/20 Due: 07/16/21

Pilot Implementation of HIV Self-testing Delivery in Private Pharmacies Combined to a Respondent Driven Sampling Method to Improve HIV Testing for MSM and TGW in Phnom Penh - ANRS 0100s

Phase: N/A Priority: Normal
NCT ID: NCT05745168 Org: User:
Start: 06/30/24 End: 10/31/26 Due: 10/31/27

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Phase: N/A Priority: Normal
NCT ID: NCT02107365 Org: User:
Start: 11/30/13 End: 04/30/15 Due: 04/30/16

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Phase: N/A Priority: Normal
NCT ID: NCT02777229 Org: User:
Start: 07/31/16 End: 07/31/21 Due: 07/31/22

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01022476 Org: User:
Start: 05/31/10 End: 05/31/13 Due: 05/31/14

ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation

Phase: N/A Priority: Normal
NCT ID: NCT05045261 Org: User:
Start: 02/01/22 End: 06/30/24 Due: 06/30/25

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

Phase: N/A Priority: Normal
NCT ID: NCT06338826 Org: User:
Start: 02/01/25 End: 09/30/27 Due: 09/30/28

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01172392 Org: User:
Start: 01/31/11 End: 06/30/15 Due: 06/30/16

Renal Transplantation and Raltegravir in HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01453192 Org: User:
Start: 12/31/11 End: 11/30/15 Due: 11/30/16

Therapeutic Option for Hepatitis B and C: a French Cohort

Phase: N/A Priority: Normal
NCT ID: NCT01953458 Org: User:
Start: 08/06/12 End: 12/31/24 Due: 12/31/25

Lipopeptide Immunisation With GTU-multiHIV Trial

Phase: N/A Priority: Normal
NCT ID: NCT01492985 Org: User:
Start: 07/31/13 End: 04/08/17 Due: 04/08/18

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

Phase: N/A Priority: Normal
NCT ID: NCT02212379 Org: User:
Start: 01/31/15 End: 04/30/18 Due: 04/30/19

Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)

Phase: N/A Priority: Normal
NCT ID: NCT05312918 Org: User:
Start: 05/31/22 End: 10/31/24 Due: 10/31/25

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

Phase: N/A Priority: Normal
NCT ID: NCT04466241 Org: User:
Start: 11/27/20 End: 11/01/21 Due: 11/01/22

Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent

Phase: N/A Priority: Normal
NCT ID: NCT01771562 Org: User:
Start: 04/30/13 End: 04/30/16 Due: 04/30/17